Protagonist Therapeutics
PTGX
128 hedge funds and large institutions have $875M invested in Protagonist Therapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 48 increasing their positions, 21 reducing their positions, and 10 closing their positions.
360% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 10
129% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 21
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more funds holding
Funds holding: 92 → 128 (+36)
20% more capital invested
Capital invested by funds: $728M → $875M (+$147M)
12.12% more ownership
Funds ownership: 101.29% → 113.41% (+12%)
76% less call options, than puts
Call options by funds: $214K | Put options by funds: $901K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$40.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$7.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$29.5M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.99M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.99M |
| 4 |
Renaissance Technologies
New York
|
-$6.48M |
| 5 |
D.E. Shaw & Co
New York
|
-$4.11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
126
IFP Advisors
Tampa,
Florida
| $1K | +$861 | +40 | New |
|
|
SPIA
127
Steward Partners Investment Advisory
New York
| $1K | +$861 | +40 | New |
|
|
AIG
128
American International Group
New York
| $369 | +$4.05K | +188 | +1% |
|
|
SI
129
Sofinnova Investments
Menlo Park,
California
| – | -$6.99M | -357,769 | Closed |
|
130
Invesco
Atlanta,
Georgia
| – | -$3.7M | -189,232 | Closed |
|
131
Arrowstreet Capital
Boston,
Massachusetts
| – | -$1.31M | -66,928 | Closed |
|
|
MAM
132
Martingale Asset Management
Boston,
Massachusetts
| – | -$855K | -43,700 | Closed |
|
|
WG
133
Winton Group
London,
United Kingdom
| – | -$642K | -32,854 | Closed |
|
|
BRA
134
Blue Rock Advisors
Wayzata,
Minnesota
| – | -$590K | -30,146 | Closed |
|
|
FIM
135
Freedom Investment Management
Hartford,
Connecticut
| – | -$212K | -10,867 | Closed |
|
136
SG Americas Securities
New York
| – | -$106K | -5,420 | Closed |
|
137
Rockefeller Capital Management
New York
| – | -$39K | -2,000 | Closed |
|
|
QT
138
Quantbot Technologies
New York
| – | -$5K | -300 | Closed |
|
PTGX Hedge Fund Activity: Q4 2020 in Review
128 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2020, worth a combined $875M — up 20% from $728M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new PTGX positions and 10 closed out — a net gain of 36 holders — while 48 added to existing stakes and 21 trimmed.
The largest buyer was BVF Inc, adding an estimated $40.9M. The largest seller was Adage Capital Partners, cutting an estimated $29.5M.
- 128 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2020, up from 92 in Q3 2020.
- Funds reported $875M of Protagonist Therapeutics stock for Q4 2020, up 20% quarter-over-quarter.
- 46 funds opened new Protagonist Therapeutics positions in Q4 2020 and 10 closed out, a net change of +36 holders.
- The largest Protagonist Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $40.9M added.
- The largest Protagonist Therapeutics seller in Q4 2020 was Adage Capital Partners, an estimated $29.5M sold.
Based on aggregated 13F filings for Q4 2020.